| |
Referred (N = 70)
|
Not Referred (N = 79)
|
P-value
|
|---|
|
Race
| | |
p = 0.66
|
|
Black
|
33 (47.1%)
|
35 (44.3%)
| |
|
White
|
21 (30.0%)
|
20 (25.3%)
| |
|
Hispanic
|
14 (20.0%)
|
19 (27.9%)
| |
|
Others
|
2 (2.9%)
|
5 (6.3%)
| |
|
Age at diagnosis (median, [IQR])
|
61 (51, 68)
|
56 (50, 64)
|
p = 0.55
|
|
Gender
| | |
p = 0.68
|
|
Male
|
9 (12.9%)
|
12 (15.2%)
| |
|
Female
|
61 (87.1%)
|
67 (84.8%)
| |
|
Insurance
| | |
p = 0.18
|
|
Private insurance
|
39 (55.7%)
|
39 (49.4%)
| |
|
Medicare
|
26 (37.1%)
|
25 (31.6%)
| |
|
Medicaid
|
2 (2.9%)
|
3 (3.8%)
| |
|
No insurance
|
3 (4.3%)
|
12 (15.2%)
| |
|
Income by ZIP code
| | |
p = 0.039
|
|
Quartile 1
|
11 (15.7%)
|
26 (32.9%)
| |
|
Quartile 2
|
17 (24.3%)
|
18 (22.8%)
| |
|
Quartile 3
|
23 (32.9%)
|
15 (19.0%)
| |
|
Quartile 4
|
19 (27.1%)
|
20 (25.3%)
| |
|
Risk factors
|
|
HTN
|
52 (74.3%)
|
32 (40.5%)
|
p < 0.0001
|
|
HLD
|
25 (35.7%)
|
23 (29.1%)
|
p = 0.39
|
|
CAD
|
12
|
0
|
p = 0.0006
|
|
Arrhythmia
|
11
|
4
|
p = 0.035
|
|
DM
|
22 (31.4%)
|
17 (21.5%)
|
p = 0.17
|
|
Smoking
|
27 (38.6%)
|
34 (42.0%)
|
p = 0.67
|
|
FH
|
20 (28.6%)
|
20 (24.7%)
|
p = 0.59
|
|
Age > 65
|
20 (28.6%)
|
14 (17.7%)
|
p = 0.12
|
|
Procedures
|
|
Coronary stents
|
4
|
0
|
p = 0.13
|
|
Cardiac surgery
|
1
|
0
|
p = 1.00
|
|
Medication pre initiation of chemotherapy
|
|
Beta blocker
|
13
|
12
|
p = 0.63
|
|
ACEI/ARB
|
26
|
19
|
p = 0.08
|
|
Diuretic
|
5
|
5
|
p = 0.84
|
|
Hydralazine
|
1
|
1
|
p = 0.93
|
|
Nitrate
|
1
|
1
|
p = 0.93
|
|
MRA
|
0
|
0
|
p = 1
|
|
CCB
|
8
|
9
|
p = 0.99
|
|
Antiarrhythmic
|
0
|
0
|
p = 1
|
|
Aspirin
|
14
|
10
|
p = 0.22
|
|
Statin
|
17
|
11
|
p = 0.11
|
|
Cancer type
| | |
p = 0.005
|
|
Breast cancer
|
59 (84.3%)
|
52 (64.3%)
| |
|
Other cancer
|
11 (15.7%)
|
29 (35.8%)
| |
|
Cancer stage
| | |
p = 0.07
|
|
Stage 1
|
8 (11.4%)
|
4 (4.9%)
| |
|
Stage 2
|
38 (54.3%)
|
33 (40.7%)
| |
|
Stage 3
|
11 (15.7%)
|
18 (22.2%)
| |
|
Stage 4
|
13 (18.6%)
|
26 (32.1%)
| |
|
Chemotherapy
| | |
p = 0.036
|
|
Doxorubicin
|
22 (31.4%)
|
42 (51.9%)
| |
|
Herceptin
|
40 (57.1%)
|
34 (42.0%)
| |
|
Doxorubicin and herceptin
|
8 (11.4%)
|
5 (6.2%)
| |
